A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Inclusion Criteria:

1. Male or female age ≥ 18 years and ≤ 75 years at the time of informed consent.
2. Histologically or cytologically confirmed advanced unresectable or metastaticcolorectal cancer;
3. Anticipated life expectancy ≥3 months
4. At least one measurable lesion per RECIST1.1 criteria, and the lesion has not beentreated with radiotherapy before (unless there is definite progression of the lesionafter radiotherapy), the longest diameter of the lesion assessed by CT or MRI atbaseline is ≥10 mm (the short axis of the lymph node is ≥15 mm); previously receivedat least second-line or higher standard treatment for advanced colorectal cancer;
5. ECOG performance status 0-2 (including threshold);
6. Weight ≥40kg
7. Hematology:

• White blood cell (WBC) ≥ 3.0×10^9/L;
• Neutrophil (ANC) ≥ 1.5×10^9/L;
• Platelet (PLT) ≥ 75×10^9/L;
• Hemoglobin (Hb) ≥ 8.0g/dL

8. Hepatic and renal function:

• Total bilirubin ≤ 1.5 × ULN;
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 × ULN forpatient without liver metastasis, ≤ 5 × ULN for patients with liver metastasis;
• Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL/min as determined bythe Cockcroft-Gault equation;

9. Coagulation:

• INR≤1.5 x ULN;
• APTT≤1.5 x ULN;

10. Women of childbearing potential (WCBP) must have a negative serum pregnancy test atScreening within 14 days of dosing. WCBP, as well as male patients with partners ofWCBP, should consent to use at least one medically approved contraceptive method (e.g.surgical sterilization, oral contraceptives, intrauterine devices, abstinence orbarrier contraception combined with spermicides) during the study treatment period andfor at least 6 months after the last trial drug treatment;
11. Willingness to attend this study, to sign informed consent, to have good compliance,and to cooperate with follow-up visit.

Exclusion Criteria: 1. Pregnant or lactating, or plan to pregnant or give birth during the trial; 2. Persistent or active infection that are not controlled by treatment including but notlimited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ; 3. Patients with imaging confirmed brain metastasis or brain metastasis history (exceptpatients with stable disease within 3 months before screening and not require systemicglucorticoid therapy according to PI), pia meningeal disease, spinal cord compression; 4. Autoimmune disease or related symptoms, or previously suffered from autoimmunedisease; 5. History of splenectomy or organ transplantation; 6. Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC),gene therapy, cellular therapy or tumor vaccines; 7. Requires continued concurrent oral or intravenous therapy with any drug against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet,cidofovir). Topical use of drugs against HSV are allowed; 8. Patients plan to receive other anti-tumor therapy (including but not limited tochemotherapy, targeted therapy, immunotherapy, anti-tumor Chinese herbal therapy,etc.) during the study; 9. Patients with a known psychiatric disorder that would interfere with cooperation withthe requirements of the trial; 10. History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent; 11. History of allergic reactions attributed to compounds of similar biologicalcomposition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients forT3011; 12. History or evidence of high risk cardiovascular disease, including but not limited to: - Severe cardiac rhythm or conduction abnormalities, such as ventriculararrhythmias requiring clinical intervention, II-III degree atrioventricularblock, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female); - Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug; - Coronary angioplasty or stent implantation within 6 months prior to firstadministration of the experimental drug; - Rating of heart function as defined by the New York Heart Association (NYHA)standards>grade II; Cardiac valve abnormalities recorded by echocardiography (≥grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mildregurgitation/stenosis) were admitted, but subjects with moderate valvethickening were excluded; - Left ventricular ejection fraction (LVEF) < the center lower limit. If no lowerlimit existed, LVEF˂50%; - Poor blood pressure control after antihypertensive treatment (i.e. systolic bloodpressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg); 13. History of another malignant tumor, except the following: - Undergone potentially curative therapy and for ≥5 years prior to the first doseof study treatment and no malignancies with known active disease and lowpotential recurrence risk; - Adequately treated non-melanoma skin cancer or lentigo with no evidence ofmalignancy; - Adequately treated carcinoma in situ without evidence of disease; 14. Received live and attenuated vaccines within 4 weeks prior to initiation of studytreatment, or plan to be vaccined during the study; 15. Previous history of immunotherapy induced non-infectious pneumonitis/interstitial lungdisease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-relatedirAE that can be stably controlled by hormone replacement therapy; 16. Moderate to large amounts of pleural effusion, pericardial effusion, or ascitesrequiring drug or medical intervention (Patient may be eligible to participatefollowing discussion with investigator and approval from the sponsor); 17. Unexplained >38.5℃ fever (except for tumor induced fever judged by PI) occurs duringthe screening period, baseline period or on the day of administration, which in thejudgment of investigator, would interfere with patient participation in the study orpatient's efficacy evaluation; 18. Any condition that PI considered may confuse the trial results, interfere with thepatient's participation in the trial, or is not in the participant's best interest toparticipate in the trial, or a history of treatment or laboratory abnormalities, orother ineligibility for enrollment.